Costly Turing Drug Gets A Low-Price Competitor
Daraprim, the drug that made news in September when its price was hiked 5,000 percent, now has a competitor priced at under $1 per pill.By Carter Woodiel | October 23, 2015
Martin Shkreli, the 32-year-old CEO of Turing Pharmaceuticals, faced public outrage in September for raising the price of a potentially lifesaving drug by 5,000 percent.
Now, another company claims it can create a substitute version of the drug — at a fraction of the price. (Video via CNBC)
Imprimis Pharmaceuticals claims it can make a drug comparable to Daraprim, a drug which treats parasitic infections and is often used to treat patients whose immune system is weakened by HIV or AIDS.